Skip to content

Study · Non-randomized trial · n = 28 · 1996

10 results

Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients.

Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K

Clinical endocrinology1 Sept 1996Cited by 64 (Europe PMC)

PMID8949568 (opens in a new tab)DOI10.1046/j.1365-2265.1996.00820.x (opens in a new tab)PepBankPUB-08949568
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In GH-deficient men studied during GH substitution, atrial emptying index was lower than in matched controls.

    In plain wordsIn GH-deficient men studied during GH treatment, atrial emptying index was lower than in matched controls.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseAtrial emptying index
    Study

    n = 28

    Comparator
    Matched controls
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    However, a lower atrial emptying index than that seen among controls might indicate some diastolic disturbance and there was a definite increase in left ventricular wall thickness compared with controls (to 25.1 +/- 1.5 vs 19.7 +/- 0.4 mm, P < 0.001).
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, left ventricular wall thickness increased to 25.1 +/- 1.5 versus 19.7 +/- 0.4 mm in controls (P < 0.001).

    In plain wordsIn GH-deficient men, left ventricular walls became thicker during GH treatment compared with matched controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLeft ventricular wall thickness
    Study

    n = 28

    Comparator
    Matched controls
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Measurements

    Left ventricular wall thickness
    25.1 mm
    GH-deficient men
    Left ventricular wall thickness
    19.7 mm
    controls

    Source sentences

    Summary
    However, a lower atrial emptying index than that seen among controls might indicate some diastolic disturbance and there was a definite increase in left ventricular wall thickness compared with controls (to 25.1 +/- 1.5 vs 19.7 +/- 0.4 mm, P < 0.001).
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, resting heart rate increased with GH substitution to control levels.

    In plain wordsIn GH-deficient men, resting heart rate rose with GH treatment to control levels.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseResting heart rate
    Study

    n = 7

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Heart rate and systolic blood pressure at rest increased with GH substitution to the level of the controls, as did diastolic blood pressure after an initial reduction.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, resting systolic blood pressure increased with GH substitution to control levels.

    In plain wordsIn GH-deficient men, resting systolic blood pressure rose with GH treatment to control levels.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseResting systolic blood pressure
    Study

    n = 7

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Heart rate and systolic blood pressure at rest increased with GH substitution to the level of the controls, as did diastolic blood pressure after an initial reduction.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, diastolic blood pressure initially decreased and then increased to control levels with GH substitution.

    In plain wordsIn GH-deficient men, diastolic blood pressure first fell and then rose to control levels during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedDiastolic blood pressure
    Study

    n = 7

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Heart rate and systolic blood pressure at rest increased with GH substitution to the level of the controls, as did diastolic blood pressure after an initial reduction.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, age-adjusted exercise capacity increased during the GH substitution study.

    In plain wordsIn GH-deficient men, age-adjusted exercise capacity increased during the GH treatment study.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAge-adjusted exercise capacity
    Study

    n = 7

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Age-adjusted exercise capacity increased during the study and we found no evidence of ischaemic heart disease on exercise ECG.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  7. 07HumanNon-randomized trialSafety outcome

    In GH-deficient men studied during GH substitution, exercise ECG showed no evidence of ischaemic heart disease.

    In plain wordsIn GH-deficient men studied during GH treatment, exercise ECG showed no evidence of ischaemic heart disease.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableIschaemic heart disease on exercise ECG
    Study

    n = 7

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Age-adjusted exercise capacity increased during the study and we found no evidence of ischaemic heart disease on exercise ECG.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  8. 08HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, stroke volume increased with GH substitution.

    In plain wordsIn GH-deficient men, stroke volume increased during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseStroke volume
    Study

    n = 7

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Stroke volume increased with GH substitution, thereby normalizing the initially reduced cardiac index.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  9. 09HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, GH substitution normalized the initially reduced cardiac index.

    In plain wordsIn GH-deficient men, GH treatment normalized the initially low cardiac index.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCardiac index
    Study

    n = 7

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    Stroke volume increased with GH substitution, thereby normalizing the initially reduced cardiac index.
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.
  10. 10HumanNon-randomized trialEfficacy outcome

    In GH-deficient men receiving GH, atrial and ventricular dimensions, fractional shortening, isovolumic relaxation time, and left ventricular filling A/E ratio did not change significantly.

    In plain wordsIn GH-deficient men receiving GH, cardiac dimensions and the reported measures of systolic and diastolic function did not change significantly.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeCardiac dimensions and systolic and diastolic function
    Study

    n = 7

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 U/kg/week · S.c.As given in this study (human).

    Source sentences

    Summary
    There was no significant change in left atrial or ventricular internal dimensions, systolic function as measured by fractional shortening, or diastolic function as measured by isovolumic relaxation time and left ventricular filling (A/E ratio).
    2 context sentences
    Summary · context
    S.c. rhGH 0.5 U/kg/week or placebo was administered in a 6-month double-blind, cross-over study, followed (after a year without substitution) by a 42-month period of open GH substitution.
    Summary · context
    We evaluated 7 GH-deficient men serially and compared the results with 21 men matched in terms of age and height.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.